Nexperia’s Court Appointees Test Investor Interest in Stake Held by China’s Wingtech

The chipmaker’s overseers will gauge demand for a majority or minority stake, a day after a Dutch court ordered Wingtech to stop interfering.

WHY IT MATTERS

Wingtech's main asset could now change hands without its consent, and a Dutch court has confirmed that the administrators may weigh export-control risks in deciding.

The two court-appointed officials who run Dutch chipmaker Nexperia on behalf of an Amsterdam court will sound out investors on buying either a majority or a minority stake in the company, the South China Morning Post reported on November 13. The Post is owned by Alibaba. "We have decided to assess market interest in possible long-term solutions for Nexperia," Guido Dierick and Arnold Croiset van Uchelen said in a statement issued on Thursday, November 12. The pair said their talks with Wingtech about possible solutions were meant to stay confidential and that they regretted its decision to make them public.

"No decision has currently been taken to reduce Wingtech’s ownership interest," the pair said. They added that the Enterprise Chamber, the Amsterdam court for corporate disputes, had confirmed that such a decision lies within their powers and that Wingtech should not interfere.

The step comes about a week after Wingtech rejected the administrators’ earlier proposal, and it reverses a stance taken in January. Then, Croiset van Uchelen told the court that a sale was not his to decide because Wingtech still owned Nexperia, even though interested buyers had come forward, the Post reported.

A court ruling cleared the way for an investor search

On Wednesday, November 11, the Enterprise Chamber found that Wingtech and Nexperia China had undermined its earlier orders, Techzine reported. It ordered Wingtech, founder Zhang Xuezheng, Nexperia China and other senior Wingtech managers to stay out of Nexperia’s normal business and to respect the court’s officials while they work on a long-term solution. According to Nexperia, the court backed its orders with significant penalties and also told Wingtech to withdraw claims in China aimed at its rulings and not to enforce injunctions a Dongguan court issued on November 2. That Chinese order barred Nexperia’s Dutch entities and three executives from selling, transferring or pledging shares, intellectual property or assets, the Post said.

The overseers say returning control to Wingtech carries export risks

The administrators’ earlier plan, whose rejection Wingtech disclosed after the market closed on November 3, would have left it in control of Nexperia’s mainland China business while outside investors took a controlling stake in everything else, leaving Wingtech with a minority, National Business Daily reported in a story carried by East Money. Wingtech said it could not accept a plan imposed without its consent and accused the administrators of discrimination against Chinese investors, while saying it remained open to talks. EastFrontier reported on the Amsterdam suit Nexperia filed against Wingtech the same week, which Wingtech says seeks US$2 billion.

In their new statement, the administrators said they were neither preparing a majority sale to outside investors nor seeking to split Nexperia into Chinese and non-Chinese businesses, and they blamed Wingtech and Nexperia China for the de facto separation. Handing control back to Wingtech would create "serious risks to Nexperia’s ability to continue operating," they said, citing export controls in several major markets. They added that the Dutch court had confirmed they could take those risks into account, the Post reported.

That leaves Wingtech in an unusual position: it remains Nexperia’s owner, but it has no say over how the company is run, and the administrators, not Wingtech, will decide whether to bring in an outside investor.

Wingtech fights on in court as its shares slide

Wingtech had not responded to the stake plan by Sunday. On the evening of November 13, it filed an announcement on a separate case: the commercial division of the Hague District Court had rejected, in an interim ruling on November 2, Nexperia B.V.’s trademark claims and its request for an injunction against Nexperia China in the EU and Benelux, according to a Securities Times report carried by 10jqka. The same ruling barred Nexperia China from relying on a Jiangsu High People’s Court (江苏省高级人民法院) order within the EU. Wingtech also disclosed that the Jiangsu court had fined Nexperia B.V. RMB58 million for not fully complying with its ruling, China.com reported.

Wingtech’s shares fell 6% on November 13 to RMB11.28, valuing the company at about RMB14.9 billion. Its revenue for the first nine months of 2026 dropped 93.11% to RMB2.05 billion, which it attributed to the sale of its product-integration business and its loss of control over Nexperia’s overseas entities, and the stock trades under a delisting risk warning as *ST Wingtech. The next markers are whether Wingtech withdraws its Chinese claims as the Amsterdam court ordered or Dutch penalties begin to accrue, and whether any investor publicly declares an interest in the stake.